Transmedics panel defies expectations

The uncharacteristically negative attitude the FDA took earlier this week, before yesterday’s panel meeting assessing Transmedics’ OCS Liver system, had spooked the group’s investors, who sent the company’s stock down 5% before the shares were halted yesterday. Now those who sold up are doubtless regretting their skittishness.